Urinary Tract Carcinoma — Trials

Urinary Tract Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

852 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 326
Recruiting: 177
Ph III recruiting: 26
Growth YoY: +28.6%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (127)

clinicaltrialsPublishedShowing 851–852 of 852 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00192049	A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer	completed	Phase 2	90	Eli Lilly and CompanyINDUSTRY	1	May 17, 2007	clinicaltrials
NCT00191711	Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.	completed	Phase 2	43	Eli Lilly and CompanyINDUSTRY	1	Jan 26, 2007